Inductive launches Beacon-2 to turn drug properties into one dose estimate
Inductive's Josh Haimson and Ben Birnbaum are pairing the dose model with Indy, their new medicinal chemistry agent, inside live partner programs.
By RuntimeWire Staff · Published
Primary source: PR Newswire
Why it matters
Beacon-2 moves Inductive beyond predicting isolated drug properties and into ranking compounds by a clinically meaningful endpoint. Its value will depend on prospective evidence that modeled dose estimates improve real laboratory and development decisions.
Josh Haimson, co-founder and CEO of Inductive, launched Beacon-2 on September 17th, giving chemists and AI agents a system for estimating the efficacious human dose of a small molecule directly from its chemical structure.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.